1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Immune Checkpoint Inhibitors Market by Type and Application : Global Opportunity Analysis and Industry Forecast, 2021-2030

Immune Checkpoint Inhibitors Market by Type and Application : Global Opportunity Analysis and Industry Forecast, 2021-2030

  • January 2022
  • 160 pages
  • ID: 5591577
  • Format: PDF
  • Allied Market Research

Summary

Table of Contents

Immune Checkpoint Inhibitors Market by Type (PD-1 Inhibitors, PD-L1 Inhibitors and CTLA-4 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma and other application): Global Opportunity Analysis and Industry Forecast, 2021-2030


The global immune checkpoint inhibitors market was valued at $29,803.71 million in 2020, and is projected to reach $1,40,890.10 million by 2030, registering a CAGR of 16.8% from 2021 to 2030
Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including, CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1).

Immune checkpoint inhibitor is also known as checkpoint inhibitor therapy is a form of cancer immunotherapy. Which used in the treatment of a broad spectrum of cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These are humanized monoclonal antibodies target inhibitory receptors (e.g. CTLA-4, PD-1, LAG-3, TIM-3) and ligands (PD-L1) expressed on T lymphocytes, antigen presenting cells and tumor cells and elicit an anti-tumor response by stimulating immune system.

The key factor that drives the growth of market are owing to the growth in incidence of different forms of cancer, surge in awareness of checkpoint inhibitor for treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population, and technological advancement in screening & diagnosis of cancer further drives the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.
The global immune checkpoint inhibitor market is segmented based on type, application, and region. Based on type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According to the application, the market is categorized as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others.
Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).
Key players operating in the global immune checkpoint inhibitor market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd Shanghai Jhunsi Biosciences Ltd.

KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global immune checkpoint inhibitors market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the products and end users of immune checkpoint inhibitors used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Type
CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor
By Application
Lung Cancer
Bladder Cancer
Melanoma
Hodgkin lymphoma
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Rest of LAMEA
KEY Players
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Sanofi
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
BeiGene Ltd
Shanghai Jhunsi Biosciences Ltd

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Intraoperative Radiation Therapy Market Research Report by Type, Method, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 3949
  • July 2022
  • 258 pages

Intraoperative Radiation Therapy Market Research Report by Type (Products and Services), Method, Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast ...

  • World
  • Cancer
  • Research And Development
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on